Literature DB >> 31994463

Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia.

Hussein K Al-Hakeim1, Abbas F Almulla2, Arafat H Al-Dujaili3, Michael Maes4,5,6.   

Abstract

BACKGROUND: In schizophrenia, pathway-genotypes may be constructed by combining interrelated immune biomarkers with changes in specific neurocognitive functions that represent aberrations in brain neuronal circuits. These constructs provide an insight on the phenome of schizophrenia and show how pathway-phenotypes mediate the effects of genome X environmentome interactions on the symptomatology/phenomenology of schizophrenia. Nevertheless, there is a lack of knowledge how to construct pathway-phenotypes using Partial Least Squares (PLS) path modeling and Soft Independent Modeling of Class Analogy (SIMCA). AIMS: This paper aims to provide a step-by-step utilization guide for the construction of pathwayphenotypes that reflect aberrations in the neuroimmune - brain circuit axis (NIBCA) in deficit schizophrenia. METHODS AND
RESULTS: This NIBCA index is constructed using immune biomarkers (CCL-2, CCL-11, IL-1β, sIL-1RA, TNF-α, sTNFR1, sTNFR2) and neurocognitive tests (Brief Assessment of Cognition in Schizophrenia) predicting overall severity of schizophrenia (OSOS) in 120 deficit SCZ and 54 healthy participants. Using SmartPLS path analysis, a latent vector is extracted from those biomarkers and cognitive tests, which shows good construct reliability (Cronbach alpha and composite reliability) and replicability and which is reflectively measured through its NIBCA manifestations. This NIBCA pathwayphenotype explains 75.0% of the variance in PHEMN (psychotic, hostility, excitation, mannerism and negative) symptoms. Using SIMCA, we constructed a NIBCA pathway-class that defines deficit schizophrenia as a qualitatively distinct nosological entity, which allows patients with deficit schizophrenia to be authenticated as belonging to the deficit schizophrenia class.
CONCLUSION: In conclusion, our nomothetic approach to develop a nomological network combining neuro-immune and neurocognitive phenome markers to predict OSOS and cross-validate a diagnostic class generated replicable models reflecting the key phenome of the illness, which may mediate the effects of genome X environmentome interactions on the final outcome phenome features, namely symptomatology and phenomenology. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cognition; Cytokines; Deficit schizophrenia; Inflammation; Machine learning; Neuro-immune.

Mesh:

Substances:

Year:  2020        PMID: 31994463     DOI: 10.2174/1568026620666200128143948

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  7 in total

1.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

2.  In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy.

Authors:  Hussein Kadhem Al-Hakeim; Rana Fadhil Mousa; Arafat Hussein Al-Dujaili; Michael Maes
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

Review 3.  How to construct neuroscience-informed psychiatric classification? Towards nomothetic networks psychiatry.

Authors:  Drozdstoy Stoyanov; Michael Hj Maes
Journal:  World J Psychiatry       Date:  2021-01-19

4.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

5.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

6.  False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway Classes.

Authors:  Michael Maes; George Anderson
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

7.  Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self.

Authors:  Michael Maes
Journal:  J Pers Med       Date:  2022-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.